Key Takeaways
- Ikarovec Ltd and VectorBuilder have entered into an exclusive worldwide option agreement for VectorBuilder’s novel AAV capsid technology to be used in combination with Ikarovec’s gene therapy candidate IKAR-003 for intermediate age-related macular degeneration (AMD).
- The proposed deal is expected to be worth over $1 billion and will enable the delivery of IKAR-003 via a minimally invasive intravitreal route in a doctor’s office.
- IKAR-003 is designed to prevent the progression of intermediate AMD to sight-threatening disease through a one-time injection of an AAV-delivered dual-pathway gene therapy.
- The partnership between Ikarovec and VectorBuilder aims to create a strong foundation for developing transformative therapies for patients with vision-threatening retinal diseases.
Introduction to Ikarovec and VectorBuilder
Ikarovec Ltd, a UK-based biotechnology company, and VectorBuilder, a global leader in gene delivery technologies, have announced an exclusive worldwide option agreement for the use of VectorBuilder’s novel AAV capsid technology in combination with Ikarovec’s gene therapy candidate IKAR-003 for intermediate age-related macular degeneration (AMD). This partnership aims to develop a convenient and effective treatment for intermediate AMD, a condition that affects millions worldwide and currently has no approved drug treatments. Ikarovec is a near-clinical stage company that is pioneering dual-pathway gene therapies for vision-threatening retinal diseases, while VectorBuilder is a trusted partner for thousands of labs and biotech/pharma companies across the globe, offering a full spectrum of gene delivery solutions.
The Partnership and Its Potential
The partnership between Ikarovec and VectorBuilder has the potential to be worth over $1 billion and will enable the delivery of IKAR-003 via a minimally invasive intravitreal route in a doctor’s office. This will enhance access to the treatment for the target patient population, those at the earlier, intermediate AMD stage for whom prevention of disease progression is a priority. IKAR-003 is designed to prevent the progression of intermediate AMD to sight-threatening disease through a one-time injection of an AAV-delivered dual-pathway gene therapy combining neuroprotection and complement modulation to preserve visual function. According to Thomas Ciulla, MD, MBA, President and CEO of Ikarovec, "Partnering with VectorBuilder on IKAR-003 increases the value of Ikarovec’s pipeline by creating an office-based intravitreally delivered product, ideal for large-scale adoption in the prevention of disease progression setting."
VectorBuilder’s Novel Capsid Technology
VectorBuilder’s proprietary capsid technology will allow IKAR-003 to be delivered to the eye via the minimally invasive intravitreal route in a doctor’s office. This technology has been engineered using VectorBuilder’s AI-powered DeepCap platform, which combines machine learning and rational design with massively parallel ultradeep search of distributed sequence space. The resulting capsids have best-in-class transduction efficiency and tissue specificity, and have demonstrated broader and more robust transduction than current clinical intravitreal capsids in non-human primate studies. According to Dr. Bruce Lahn, Founder and Chief Scientist at VectorBuilder, "By utilizing our AI-powered DeepCap platform, we were able to engineer best-in-class ocular capsids that can target wide areas of the retina and successfully transduce virtually all cells of the macula."
Ikarovec’s Dual-Pathway Gene Therapy Approach
Ikarovec’s dual-pathway gene therapy approach combines two synergistic mechanisms to address the complex pathology of vision-threatening retinal diseases. The company’s lead programmes, including IKAR-003 and IKAR-001, are designed to address large market opportunities in geographic atrophy, retinitis pigmentosa, intermediate AMD, and wet AMD. IKAR-003 uses the same dual-pathway approach as IKAR-001, which remains on track for clinical trial initiation in late 2026 in geographic atrophy, using validated subretinal delivery in this advanced stage of disease. By addressing two distinct patient populations with a delivery approach tailored to each, Ikarovec aims to create a strong foundation for developing transformative therapies for patients with vision-threatening retinal diseases.
Conclusion and Future Prospects
In conclusion, the partnership between Ikarovec and VectorBuilder has the potential to revolutionize the treatment of intermediate AMD and other vision-threatening retinal diseases. With VectorBuilder’s novel capsid technology and Ikarovec’s dual-pathway gene therapy approach, the companies are well-positioned to develop effective and convenient treatments for these diseases. As the global prevalence of AMD continues to grow, the need for innovative and effective treatments has never been more pressing. The partnership between Ikarovec and VectorBuilder is an important step towards addressing this need and improving the lives of millions of people worldwide. With the proposed deal expected to be worth over $1 billion, the companies are poised to make a significant impact in the field of ophthalmology and beyond.